TherapeuticsMD
TXMD
42 hedge funds and large institutions have $3.78M invested in TherapeuticsMD in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 2 closing their positions.
22% more capital invested
Capital invested by funds: $3.09M → $3.78M (+$684K)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
0% more funds holding
Funds holding: 42 → 42 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.77% less ownership
Funds ownership: 28.9% → 28.13% (-0.77%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$5.24K |
| 2 |
Renaissance Technologies
New York
|
+$1.7K |
| 3 |
Raymond James Financial
St Petersburg,
Florida
|
+$645 |
| 4 |
Citigroup
New York
|
+$246 |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$236 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$73.9K |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$20.8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.56K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$3.31K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.17K |
TXMD Hedge Fund Activity: Q2 2025 in Review
42 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q2 2025, worth a combined $3.78M — up 22% from $3.09M a quarter earlier.
Fund positioning in TXMD was balanced in Q2 2025: 2 funds opened new positions, 2 closed out, 9 added to existing stakes and 8 trimmed.
The largest buyer was UBS Group, adding an estimated $5.24K. The largest seller was ADAR1 Capital Management, cutting an estimated $73.9K.
- 42 institutional investors held TherapeuticsMD (TXMD) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $3.78M of TherapeuticsMD stock for Q2 2025, up 22% quarter-over-quarter.
- 2 funds opened new TherapeuticsMD positions in Q2 2025 and 2 closed out, a net change of 0 holders.
- The largest TherapeuticsMD buyer in Q2 2025 was UBS Group, an estimated $5.24K added.
- The largest TherapeuticsMD seller in Q2 2025 was ADAR1 Capital Management, an estimated $73.9K sold.
Based on aggregated 13F filings for Q2 2025.